icd 9 code for stenotrophomonas maltophilia

How is Stenotrophomonas maltophilia diagnosed?

Nov 27, 2018 · Stenotrophomonas maltophilia (S. maltophilia) infection is a type of bacterial infection.S. maltophilia is found mostly in wet environments. In the hospital setting, S. maltophilia can be found in fluids, such as irrigation solutions (fluids used to clean a wound or wash out a body cavity like the ear canal or bladder) and intravenous (IV) fluids, as well as patient …

Where is Staphylococcus maltophilia found?

Jan 17, 2022 · Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: ... Ninth Revision diagnosis codes 481, 485, 486, 514; or ICD, Tenth Revision diagnosis codes J18.0, J18.1, J18.2, J18.8, J18.9. Day –1 …

What are the signs and symptoms of Streptococcus maltophilia infection?

A GToTree v1.5.47 phylogenomic analysis using 172 gammaproteobacterium single-copy genes in 204 S. maltophilia reference strains and Stenotrophomonas pictorum JCM 9942 as an outgroup suggested that S. maltophilia 1800 belongs …

Can you get S maltophilia from a hospital?

Burns of 10-19% of body surfc w 0% to 9% third degree burns; Burn any degree involving 10-19 percent of body surface; Burn any degree involving 10-19 percent of body surface with third degree burn less than 10 percent of body surface; Burn injury; Burns involving 10 …

What diseases are caused by Stenotrophomonas maltophilia?

maltophilia experience infections of the heart (endocarditis), the bone behind the ear (mastoiditis), lining of the abdomen and internal organs (peritonitis), cerebral spinal fluid ( meningitis ), soft tissue , wounds, urinary tract, and/or eye. The symptoms are similar to other bacterial infections of the same sites.

What is Stenotrophomonas infection?

Stenotrophomonas (Xanthomonas) maltophilia is a multidrug-resistant gram-negative bacillus that is an opportunistic pathogen [1-4], particularly among hospitalized patients. S. maltophilia infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals.

Is Stenotrophomonas maltophilia the same as Pseudomonas?

Stenotrophomonas maltophilia is an opportunistic pathogen that was transferred from the genus Pseudomonas via the Xanthomonas group to the newly defined genus Stenotrophomonas.

Where is Stenotrophomonas maltophilia found?

Stenotrophomonas maltophilia (SMA) is a non-fermenting gram-negative bacillus found in plants and soil and on the surface of human skin. It is present in hospital environments and is detected in the respiratory and intestinal tracts.Dec 21, 2019

How do you treat Stenotrophomonas maltophilia?

The treatment of choice for Stenotrophomonas maltophilia is trimethoprim-sulfamethoxazole (SXT). Fluoroquinolones (FQs) have in vitro activity against S.

Where are Stenotrophomonas from?

S. maltophilia is an environmental bacterium found in aqueous habitats, including plant rhizospheres, animals, foods, and water sources. Infections of S. maltophilia can occur in a range of organs and tissues; the organism is commonly found in respiratory tract infections.

What type of organism is Stenotrophomonas?

Stenotrophomonas maltophiliaStenotrophomonas maltophilia clinical isolates on MacConkey agarScientific classificationDomain:BacteriaPhylum:Pseudomonadota10 more rows

What does Stenotrophomonas cause?

maltophilia causes various infectious complications in immunocompromised individuals and these include bacteremia, endocarditis, respiratory tract infections, meningitis, urinary tract infections, skin and soft tissue infections, mastoiditis, bone and joint infections, peritonitis, typhlitis and biliary sepsis, wound ...Aug 25, 2014

What is the shape of Stenotrophomonas?

Stenotrophomonas maltophilia is an aerobic, Gram-negative, rod-shaped bacterium of the Xanthomonadaceae family. It may trigger urinary tract infection, respiratory tract infection or bloodstream infection.

Does meropenem cover Stenotrophomonas maltophilia?

The susceptibility of 20 clinical isolates of Stenotrophomonas maltophilia to the carbapenems imipenem and meropenem was investigated by various methods. S. maltophilia appeared sensitive to meropenem but resistant to imipenem by disc testing in Iso-sensitest agar.

How do you get rid of Stenotrophomonas?

Trimethoprim-Sulfamethoxazole (TMP-SMX) The mainstay of treatment for Stenotrophomonas infections is trimethoprim-sulfamethoxazole (TMP-SMX) and it remains the current drug of choice.Oct 9, 2021

How many cases of Stenotrophomonas are there?

Stenotrophomonas maltophilia represents the fourth most common pathogen among nonfermenting gram-negative bacteria (following Pseudomonas aeruginosa, Acinetobacter spp, and Burkholderia cepacia complex), with a reported incidence of 7.1 to 37.7 cases/10 000 discharges (regarding nosocomial infections)20.Aug 15, 2019

Abstract

Trimethoprim-sulfamethoxazole (TMP-SMX) is considered first-line therapy for Stenotrophomonas maltophilia infections based on observational data from small studies. Levofloxacin has emerged as a popular alternative due to tolerability concerns related to TMP-SMX. Data comparing levofloxacin to TMP-SMX as targeted therapy are lacking.

METHODS

The Cerner Healthfacts database was queried for unique adult (≥18 years) inpatient encounters admitted between 1 January 2005 and 31 December 2017 that recorded growth of S maltophilia in ≥1 blood or lower respiratory tract culture. The latter included sputum, tracheal aspirate, bronchoalveolar lavage, and protected bronchial brush washings.

RESULTS

Between 2005 and 2017, there were 14 930 unique inpatients at 154 hospitals in the United States with any culture positive for S maltophilia in the database. After applying selection criteria ( Figure 1 ), 1581 assessable inpatients were identified: 823 (52%) inpatients in the levofloxacin cohort and 758 (48%) in the TMP-SMX cohort.

DISCUSSION

Our study of 1581 patients from 154 US hospitals represents the largest retrospective cohort analysis thus far comparing the effectiveness of levofloxacin vs TMP-SMX as targeted therapy for S maltophilia bloodstream and lower respiratory tract infections.

CONCLUSIONS

Our large study of overlap-weighted cohorts of patients treated with levofloxacin vs TMP-SMX for S maltophilia LRTIs and BSIs suggest that levofloxacin might be a reasonable alternative to the current accepted standard TMP-SMX for these infections. An RCT comparing levofloxacin and TMP-SMX head-to-head is yet to be performed.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. S. S. K. conceived the study. S. H. S. and S. S. K. designed the study, conducted the literature search, and wrote the draft of the manuscript. S. H. S., S. W., and S. S. K. collected and analyzed the data. S. H. S., S. W., S. S. K., R. M., and V. G. F. interpreted the data.

Abstract

Methods

• Study Design and Case Selection
  The Cerner Healthfacts database was queried for unique adult (≥18 years) inpatient encounters admitted between 1 January 2005 and 31 December 2017 that recorded growth of S maltophilia in ≥1 blood or lower respiratory tract culture. The latter included sputum, tracheal aspirate, bron…
• Patient Consent Statement
  Given that the study exclusively used deidentified data, it was deemed not to require patient consent and was deemed exempt from ethics board review at the National Institutes of Health (NIH) Clinical Center, based on the policy of the NIH Office of Human Subjects Research Protect…

See more on academic.oup.com

Results

Discussion

Conclusions

Supplementary Data

Notes